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Abstract 
Dexmedetomidine is used for sedation during spinal anesthesia. The sympatholytic effect of 
dexmedetomidine may exacerbate hypotension and bradycardia with spinal anesthesia. This study 
investigated the effects of prophylactic intramuscular injection of ephedrine in preventing hypotension 
and bradycardia occurring through combined use of spinal anesthesia and dexmedetomidine. One 
hundred sixteen patients scheduled for lower extremity orthopedic surgery were randomized into two 
groups receiving either ephedrine 20 mg intramuscularly or equivalent amount of 0.9% NaCl, both with 
dexmedetomidine and spinal anesthesia. The primary endpoint was the incidence of hemodynamic 
perturbations (hypotension or bradycardia event). The secondary endpoint was a rescue doses of 
ephedrine and atropine. The incidence of hemodynamic perturbations was significantly lower in the 
ephedrine group compared with to the saline group (26.3% versus 55.9%, p = 0.001). The rescue doses of 
atropine (0.09 ± 0.21 versus 0.28 ± 0.41, p = 0.001) and ephedrine (1.04 ± 2.89 versus 2.03 ± 3.25, p = 
0.007) were also significantly lower in the ephedrine group. There was no differences in number of 
patients with hypertensive (7.0% versus 11.9%, p = 0.375) or tachycardia (1.8% versus 3.4% p = 0.581) 
episodes. The use of ephedrine intramuscular injections may be a safe and efficacious option in preventing 
hemodynamic perturbations in patients who received spinal anesthesia and sedation using 
dexmedetomidine. 
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Introduction 
Proper sedation during spinal anesthesia has 
become essential in the current anesthetic practice in 
terms of patient satisfaction and compliance of 
regional anesthesia [1]. However, sedation is 
inevitably accompanied by respiratory depression [2]. 
To provide a safe operative milieu for patients 
undergoing spinal anesthesia requiring sedation, 
continuous infusion of dexmedetomidine has gained 
wide-spread popularity [3].  
Dexmedetomidine, a highly selective alpha-2 
adrenoceptor agonist, is a unique sedative that has the 
benefits of analgesic, sympatholytic, and 
respiratory-preserving properties [4]. Intravenous 
administration of dexmedetomidine during spinal 
anesthesia also conveys advantages in terms of 
prolonging sensory and motor blocks [5], and 
reducing the amount of necessary postoperative 
analgesics [6, 7]. However, dexmedetomidine reduces 
central sympathetic outflow, leading to decrease in 
blood pressure and heart rate (HR) [8], which may be 
aggravated by spinal anesthesia-induced blockage of 
the sympathetic nervous systems [9]. Several studies 
have demonstrated that use of dexmedetomidine 
during spinal anesthesia increased the frequency of 
bradycardia and hypotension [10-12].  








possessing both direct and indirect effects, and has 
long been the drug of choice in managing spinal 
anesthesia-induced hemodynamic perturbations [13]. 
However, ephedrine is not suitable for continuous 
infusion. Repeated intermittent intravenous bolus 
administration of ephedrine is a reactive treatment 
rather than a preventive one and inevitably results in 
oscillations of peak and trough drug levels [14]. To 
overcome these potential shortcomings, the efficacy of 
a single intramuscular (IM) ephedrine injection to 
prevent spinal anesthesia-induced bradycardia or 
hypotension has been validated by previous studies 
that exhibited promising results [15]. Unfortunately, 
evidence in that regard is lacking in patients receiving 
dexmedetomidine during spinal anesthesia.  
The primary aim of this randomized controlled 
study was to investigate the efficacy of prophylactic 
IM ephedrine injection in preventing spinal 
anesthesia-induced hemodynamic perturbations 
(events of bradycardia or hypotension) in patients 
undergoing lower extremity orthopedic surgery. 
Method  
Study population  
The current trial was approved by the 
Institutional Review Board of Yonsei University 
Wonju College of Medicine, Wonju, Korea, enlisted in 
https://cris.nih.go.kr (KCT0002833), and followed 
the CONsolidated Standards of Reporting Trials 
(CONSORT) 2010 guidelines. After acquiring 
informed consent from each patient, 120 patients with 
American Society of Anesthesiologist physical status 
I, II or III aged 20-80 years, who underwent lower 
extremity orthopedic surgery under spinal anesthesia 
between December 2017 and July 2019 were enrolled. 
Patients with a history of heart failure, recent 
myocardial infarction and/or stroke (within 3 months 
of surgery), cognitive impairment, hepatic 
dysfunction, or failed spinal anesthesia were excluded 
from the study. Patients were randomly and evenly 
assigned to either the IM ephedrine or control group 
by a computerized randomized table. Blinding of the 
group designation was maintained to the patients, 
attending anesthesiologists, and interventionists, 
while the studied drugs were prepared by an 
anesthesia nurse who was not involved in patient care 
or assessment.  
Anesthetic and procedural management  
For premedication, patients received an IM 
injection of midazolam 1 mg before entering the 
operating room. In the operating room, ECG, 
non-invasive blood pressure, pulse-oximetry (SpO2), 
and respiratory rates were monitored in all patients. 
Before spinal anesthesia, hydration with balanced 
isotonic crystalloid 6 ml/kg intravenous 
administration was performed.  
Spinal anesthesia was performed in the lateral 
decubitus position using a midline approach at the 
L3/4 or L4/5 intervertebral space. Intrathecal 
injection of 10 to 12 mg hyperbaric bupivacaine 
(Marcaine®, AstraZeneca AB, Södertälje, Sweden) was 
administered according to height, weight, age of 
patients and target sensory level of the blocks. The 
level of block was assessed by loss of pinprick 
sensation in the mid-clavicular line using a 26-gauge 
needle.  
After confirmation of appropriate block height, 
dexmedetomidine infusion was initiated based on 
previous studies [16]. In both groups, 
dexmedetomidine 1.0 μg/kg was administered for 10 
minutes followed by continuous infusion of 0.2-0.7 
μg/kg/h until the end of surgery. Dose adjustments 
were performed to target a Ramsay sedation score 
between 2 and 4 (1 = anxious and agitated, restless; 2 
= co-operative, oriented and tranquil; 3 = response to 
commands only; 4 = brisk response; 5 = sluggish 
response to light glabellar tap or loud auditory 
stimuli; 6 = no response to stimulation) [17]. At the 
beginning of dexmedetomidine loading dose infusion, 
patients in the IM ephedrine group received 20 mg of 
ephedrine into the ventrogluteal region (opposite the 
surgical site) in a total volume of 2 ml mixed with 
0.9% saline, and patients in the control group received 
the equivalent amount of 0.9% saline.  
The baseline point was defined as the starting 
point of dexmedetomidine loading. Hemodynamic 
data were serially recorded at 3, 5, 10, 30, 60, 90, and 
120 minutes after baseline. If hypotension (mean 
arterial pressure (MAP) < 60 mmHg or > 30% 
decrease in MAP compared with the preanesthetic 
rate) occurred, 4-8 mg of ephedrine was administered 
intravenously. If bradycardia (HR < 45 bpm or > 30% 
decrease in HR compared with the preanesthetic rate) 
occurred, 0.5 mg of atropine was administered 
intravenously. If hypertension (systolic arterial 
pressure > 180 mmHg or diastolic arterial pressure > 
110 mmHg) occurred, 0.5-1 mg of nicardipine 
hydrochloride was administered intravenously. If 
tachycardia (HR > 110 bpm) occurred, 5-10 mg of 
esmolol was given intravenously. If respiratory 
depression (respiratory rate < 10/min) and/ or 
hypoxia (SpO2 < 90%) occurred, patients were given a 
verbal awakening stimulation (calling their name) 
followed by a gentle squeeze at the trapezius muscle, 
if unresponsive. If respiratory depression persisted 
despite these stimulations, dexmedetomidine infusion 
was discontinued while preparing for further 
advanced airway management.  




Primary endpoint and assessment  
The primary endpoint of the current study was 
to investigate the incidence of hemodynamic 
perturbations represented by bradycardia and/or 
hypotensive (defined as above) events between the 
groups. 
Secondary endpoints  
The secondary endpoints of the current study 
were to determine the total amounts of rescue 
ephedrine and atropine and the incidences of 
hypertensive and tachycardia events, and 
nausea/vomiting requiring treatment between the 
groups.  
Statistical analysis  
Sample size calculation was executed based on 
incidence of bradycardia. In a previous study, the 
incidence of bradycardia was 30% in patients with a 
combination of spinal anesthesia and 
dexmedetomidine [18]. Assuming that the use of IM 
ephedrine can reduce the incidence by 8% or more, 
the estimated number of patients in each group was 
58 patients at an α error of 0.05 and a power of 90%. 
Accounting for a dropout rate of 5%, we enrolled 60 
patients in each group.  
 All statistical analyses were performed with SAS 
9.4 and Rx64 programs. Comparative analysis of 
repeated-measurement variables was performed by 
repeated-measures analysis of variance (ANOVA) for 
between-group and within-group comparisons. 
Mauchy’s sphericity test was performed. If the 
sphericity assumption was violated, the modified 
statistic tests as Greenhouse-Geisser and Huynh-Feldt 
were used. If there was a significant interaction with 
time and group, post hoc Bonferroni corrections were 
used to correct the type I error. Hemodynamic data 
that were serially assessed at 8 time points. Therefore, 
the p values for the hemodynamic data were 
considered statistically significant when p < 0.00625. 
Otherwise, p < 0.05 was considered statistically 
significant. Proportions were compared to χ2 test and 
pairwise comparisons between the groups were 
performed with paired t-tests. Intergroup 
comparisons of variables that showed normal 
distribution were tested using the independent t- test 
(mean ± standard deviation [SD]). In cases of 
abnormal distribution, the Mann-Whitney U test was 
performed (median [interquartile range]). Intergroup 
comparisons of categorical variables were conducted 
using the Chi-square test (n [%]).  
Results  
A total of 124 patients was screened, and 120 of 
them were enrolled and randomized into either the 
ephedrine or control group. There were 4 dropouts 
among the 120 enrolled subjects due to conversion to 
general anesthesia (Figure 1).  
Patient characteristics and procedural data are 
displayed in Table 1.  
 
Table 1. Patients’ characteristics 
 Control (n = 59) Ephedrine (n = 57) P-value 
Age (yrs) 53.0 ± 16.7 54.1 ± 18.2 0.734 
Sex (M/F) 30/29 24/33 0.347 
Height (cm) 161.2 ± 11.1 162.3 ± 9.9 0.600 
Body surface area (m2) 1.72 ± 0.20 1.72 ± 0.19 0.995 
Hypertension 25 (42.4) 19 (33.3) 0.318 
Diabetes mellitus 17 (28.8) 13 (22.8) 0.462 
Chronic kidney disease 2 (3.4) 2 (3.5) 0.972 
Cerebrovascular accident 4 (6.8) 1 (1.8) 0.185 
Medications    
Beta-blocker 8 (13.6) 7 (12.3) 0.838 
ACEi 0 (0.0) 2 (3.5) 0.148 
ARB 20 (33.9) 13 (22.8) 0.188 
CCB 13 (22.0) 9 (15.8) 0.393 
Diuretics 5 (8.5) 9 (15.8) 0.229 
ASA class   0.141 
I 17 (28.8) 25 (43.9)  
II 35 (59.3) 26 (45.6)  
III 7 (11.9) 6 (10.5)  
Block height T 9.6 ± 1.7 T 9.7 ± 1.6 0.853 
Surgical time 75.08 ± 31.91 70.35 ± 33.96 0.441 
Data are displayed in mean ± SD or n (%). P value, intergroup comparison between 
the control and ephedrine group; ACEi, angiotensin converting enzyme inhibitor; 
ARB, angiotensin receptor blocker; CCB, calcium channel blocker; ASA, American 
Society of Anesthesiologists; T, thoracic dermatome. 
 
The incidence of hemodynamic perturbations, 
which was the primary endpoint, was significantly 
lower in the IM ephedrine group compared with the 
control group (55.9% versus 26.3%, p = 0.001) yielding 
a statistical power of 90.3% for the primary outcome 
variable. 
The total doses of rescue atropine (0.28 ± 0.41 
versus 0.09 ± 0.21, p = 0.001) and ephedrine (2.03 ± 
3.25 versus 1.04 ± 2.89, p = 0.007), which were the 
secondary endpoint of the study were also 
significantly lower in the ephedrine group. The 
number of patients with one or more hypertensive 
(11.9% versus 7.0%, p = 0.375) or tachycardia (3.4% 
versus 1.8%, p = 0.581) episodes did not differ 
between the groups. The intraoperative (3.4% versus 
5.3%, p = 0.621) and postoperative (69.5% versus 
63.2%, p = 0.472) anti-emetic requirements were also 
similar between the groups (Table 2.).  
The serially assessed HR (baseline p = 0.042, 3 
min p = 0.222, 5 min p = 0.139, 10 min p = 0.869, 30 
min p = 0.037, 60 min p = 0.022, 90 min p = 0.046, 120 
min p = 0.053) and MAP (baseline p = 0.608, 3 min p = 
0.453, 5 min p = 0.389, 10 min p = 0.798, 30 min p = 
0.327, 60 min p = 0.020, 90 min p = 0.959, 120 min p = 
0.439) did not exhibit any significant intergroup 
differences. In both groups, HR was significantly 
decreased at all-time points compared to their 
corresponding baseline value (all time points p < 




0.001) without 120 min in the ephedrine group (p = 
0.007). MAP was also decreased at 60 min, 90 min 
time points compared to their corresponding baseline 
value in control group (3 min p = 0.013, 5 min p = 
0.335, 10 min p = 0.437, 30 min p = 0.019, 60 min p < 
0.001*, 90 min p = 0.001*, 120 min p = 0.473) and 
decreased at 90 min time points in ephedrine group (3 
min p = 0.032, 5 min p = 0.274, 10 min p = 0.292, 30 
min p = 0.407, 60 min p = 0.021, 90 min p = 0.004*, 120 
min p = 0.018) (Figure 2.). 
Discussion  
In the current trial, we found that pre-emptive 
IM ephedrine injection was efficacious in terms of 
reducing the incidence of hypotension or bradycardia 
and the requirements of rescue ephedrine or atropine 
in patients who received spinal anesthesia combined 
with sedation via continuous infusion of 
dexmedetomidine. 
 
Table 2. Primary and secondary endpoints. 
 Control (n=59) Ephedrine (n=57) P-value  
Primary endpoint    
Overall  33 (55.9) 15 (26.3) 0.001* 
Bradycardia 20 (33.9) 8 (14.0) 0.013* 
Hypotension 16 (27.1) 9 (15.8) 0.140 
Secondary endpoints    
Atropine (mg)  0.28 ± 0.41 0.09 ± 0.21 0.001* 
Ephedrine (mg)  2.03 ± 3.25 1.04 ± 2.89 0.007* 
Adverse events     
Intra OP hypertension  7 (11.9) 4 (7.0) 0.375 
Intra OP tachycardia 2 (3.4) 1 (1.8) 0.581 
Intra OP anti-emetics 2 (3.4) 3 (5.3) 0.621 
Post OP anti-emetics  41 (69.5) 36 (63.2) 0.472 
Data are displayed in n (%) or mean ± SD, *P <0.05, intergroup comparisons 





Figure 1. Flow chart of patient enrollment. Of the 124 patients, 4 were excluded for failure of spinal anesthesia and 4 were discontinued intervention for conversion to the 
general anesthesia. 





Figure 2. Hemodynamic data showing no significant intergroup differences between the control and ephedrine group: A) Heart rate (p = 0.584); B) Mean arterial pressure (p = 
0.505). The x-axis represents the time point from preanesthetic point through 120 minutes. Preanesthetic, before performing spinal anesthesia; baseline, starting the loading dose 
of dexmedetomidine; *p <0.05, compared with the corresponding baseline value. 
 
Sedation using dexmedetomidine provides 
several potential benefits. First, dexmedetomidine is 
known to preserve spontaneous respiration and has 
the least potential to cause airway compromise among 
the commonly used sedatives [19]. Second, sedation 
with dexmedetomidine elicits similar 
electroencephalography patterns to physiologic sleep 
[20], which may be beneficial in terms of 
postoperative delirium [21]. Accordingly, patients can 
readily recover purposeful responsiveness, if 
necessary [22]. Third, dexmedetomidine is unique 
among the sedatives in that it can also provide 
analgesia [19]. Of particular relevance to spinal 
anesthesia, both intrathecal and intravenous 
administration of dexmedetomidine extend the 
duration of sensory and motor blockades, deepen 
sedation, delay the time required for postoperative 
rescue analgesics, and reduce consumption of 
morphine during the postoperative 24 hours [18, 23]. 
Indeed, cumulating evidence shows that 
dexmedetomidine is superior in terms of satisfaction 
for both patient and interventionists compared with 
midazolam [16, 24-26]. In addition, patients sedated 
with dexmedetomidine exhibited lower pain values 
and lower analgesic requirements postoperatively [26, 
27].  
 However, being an alpha-2 agonist, 
dexmedetomidine use can result in bradycardia and 
hypotension caused by central sympatholytic effects 
[28]. In theory, these sympatholytic features of 
dexmedetomidine could impose an incremental risk 
of hemodynamic perturbations by spinal 
anesthesia-induced sympathetic blockades when used 
in combination. In the literature, combined use of 
spinal anesthesia with dexmedetomidine increased 
the incidence of hypotension (16% versus 10%) and 
bradycardia (30% versus 0%) compared with spinal 
anesthesia alone in patients undergoing lower 
extremity surgery [18], mandating the need for an 
effective preventive measure to counteract the 
hemodynamic perturbations.  
Ephedrine is a non-specific alpha and beta 
sympathetic agonist with a predominant beta effect 
that increases systolic blood pressure by increasing 
stroke volume and HR [13]. Ephedrine is the most 
common rescue cardiotonic drug for treatment of 
hypotension accompanied by neuraxial anesthesia. 
Ephedrine is cost-effective and relatively safe to use in 
variety of patients receiving anesthetic care, even 
without an invasive arterial line. However, the 
pharmacokinetic properties of ephedrine do not allow 
continuous intravenous infusion, and it is mostly 
administered as intermittent intravenous bolus that 
results in peaks and troughs of plasma drug 
concentration. Moreover, considering that the 
potential ischemic harm conveyed by reduced MAP 
to major organs is dependent on the cumulative time 
spent below that low MAP [29], proactive treatments 
to maintain stable MAP and cardiac output instead of 
reactive treatments should be more encouraged. For 
that purpose, use of IM ephedrine has long been 
considered an efficacious and cost-effective method as 
it can provide continuous and sustained release of the 
drug [30]. On the other hand, IM injection is usually 
discouraged due to the unpredictable onset or offset. 
Yet, previous studies have depicted a relatively 
reliable onset time of 15 to 20 minutes with its effects 
not lasting longer than 2 hours [15]. Previous studies 
addressing the efficacy of pre-emptive IM ephedrine 
in spinal anesthesia showed promising results 
regarding the preventive effect of hemodynamic 
perturbations without untoward hypertensive or 




tachycardia side-effects [15, 31], including those 
undergoing Caesarean section requiring a high level 
of spinal block [32, 33]. Evidence is lacking regarding 
the efficacy of pre-emptive IM ephedrine treatment in 
patients who received spinal anesthesia in 
combination with sedation using dexmedetomidine. 
In the present study, we showed that ephedrine 20 mg 
IM injection reduced hemodynamic perturbations in 
spinal anesthesia with dexmedetomidine (55.9% 
versus 26.3%, p = 0.001). It is meaningful to obtain 
hemodynamic stability through IM injection that 
maintains a constant concentration without reaching 
the peak. In addition, IM ephedrine reduced the use of 
rescue ephedrine and atropine as secondary 
endpoints. This result can be interpreted as reducing 
the severity of hypotension or bradycardia that may 
be translated into improved outcome, which merits a 
further study in that regard.  
The limitations of the current study are as 
follows. The dose of ephedrine was not determined 
according to body mass. The 20 mg IM ephedrine 
injection in all patients had not been dosed in a 
tailored fashion. Second, the mean block height of 
spinal anesthesia was T10. In the literature, the odds 
ratio of hypotension increased more than 3 times 
when the level was T5 or higher [9]. Therefore, if the 
target level had been higher, the preventive effect of 
ephedrine would have been better exhibited but 
would require an ephedrine dose higher than 20 mg, 
which was beyond the scope of the current study. 
In conclusion, a single pre-emptive ephedrine 20 
mg IM injection may be a safe and efficacious option 
to prevent sympathetic blockade-induced hemo-
dynamic perturbations manifested as hypotension or 
bradycardia in patients who received spinal 
anesthesia and sedation using dexmedetomidine.  
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